SG11202102357RA - Combination therapies - Google Patents
Combination therapiesInfo
- Publication number
- SG11202102357RA SG11202102357RA SG11202102357RA SG11202102357RA SG11202102357RA SG 11202102357R A SG11202102357R A SG 11202102357RA SG 11202102357R A SG11202102357R A SG 11202102357RA SG 11202102357R A SG11202102357R A SG 11202102357RA SG 11202102357R A SG11202102357R A SG 11202102357RA
- Authority
- SG
- Singapore
- Prior art keywords
- combination therapies
- therapies
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775628P | 2018-12-05 | 2018-12-05 | |
| PCT/US2019/064707 WO2020118066A1 (en) | 2018-12-05 | 2019-12-05 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102357RA true SG11202102357RA (en) | 2021-04-29 |
Family
ID=70973971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102357RA SG11202102357RA (en) | 2018-12-05 | 2019-12-05 | Combination therapies |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220079947A1 (en) |
| EP (1) | EP3890716A4 (en) |
| JP (1) | JP2022509724A (en) |
| KR (1) | KR20210113587A (en) |
| CN (1) | CN113164418A (en) |
| AU (1) | AU2019392683A1 (en) |
| CA (1) | CA3112129A1 (en) |
| EA (1) | EA202190630A1 (en) |
| IL (1) | IL281348A (en) |
| MX (1) | MX2021002804A (en) |
| SG (1) | SG11202102357RA (en) |
| WO (1) | WO2020118066A1 (en) |
| ZA (1) | ZA202102016B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4249000A3 (en) * | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| TWI752580B (en) * | 2019-08-07 | 2022-01-11 | 大陸商北京加科思新藥研發有限公司 | Kras mutant protein inhibitor |
| CN112694475A (en) * | 2019-10-23 | 2021-04-23 | 苏州泽璟生物制药股份有限公司 | Cycloalkyl and heterocycloalkyl inhibitors, and preparation method and application thereof |
| CN112778301A (en) * | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | Tetrahydropyridopyrimidine inhibitor and preparation method and application thereof |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| TW202144349A (en) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | Preparation and application method of heterocyclic compound as KRAS inhibitor |
| EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| CN115996717A (en) * | 2020-06-25 | 2023-04-21 | 托雷莫治疗股份公司 | Combination of CBP/P300 bromodomain inhibitors and KRAS inhibitors for the treatment of cancer |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022133731A1 (en) * | 2020-12-22 | 2022-06-30 | Novartis Ag | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers |
| CN116710094A (en) * | 2020-12-22 | 2023-09-05 | 诺华股份有限公司 | Pharmaceutical combination comprising a KRAS G12C inhibitor and use of a KRAS G12C inhibitor for the treatment of cancer |
| EP4284370A1 (en) * | 2021-01-29 | 2023-12-06 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2022247760A1 (en) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| TW202317100A (en) * | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
| WO2023168036A1 (en) * | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2024076670A2 (en) * | 2022-10-05 | 2024-04-11 | Amgen Inc. | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof |
| WO2024081363A1 (en) * | 2022-10-12 | 2024-04-18 | Revolution Medicines, Inc. | Composition comprising a first ras inhibitor, second ras inhibitor and a shp2 inhibitor for use in the treatment of cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613785B2 (en) | 1998-07-21 | 2003-09-02 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing post-ischemic injury of the heart |
| US20040043434A1 (en) | 2002-06-13 | 2004-03-04 | Gen-Sheng Feng | Shp-2 tyrosine phosphatase and embryonic stem cell differentiation |
| WO2004041216A2 (en) | 2002-11-05 | 2004-05-21 | Mount Sinai School Of Medicine Of New York University ; | Ptpn11 (shp-2) mutations and cancer |
| WO2005094314A2 (en) | 2004-03-26 | 2005-10-13 | The Burnham Institute | Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders |
| EP1728790A1 (en) | 2005-06-01 | 2006-12-06 | Max-Delbrück-Centrum Für Molekulare Medizin | Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases |
| US7547760B2 (en) | 2006-07-03 | 2009-06-16 | West Virginia University | Peptides and chemical compound for inhibition of SHP2 function |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| NL2008335A (en) | 2011-04-07 | 2012-10-09 | Asml Netherlands Bv | Lithographic apparatus, device manufacturing method, and method of correcting a mask. |
| SI3447069T1 (en) | 2012-11-21 | 2021-02-26 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
| JP6473457B2 (en) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | 1- (Triazin-3-yl / pyridazin-3-yl) -piperidine / piperazine derivatives and compositions thereof for inhibiting the activity of SHP2 |
| JP6523303B2 (en) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | 1-Pyridazin / triazin-3-yl-piperazine / piperidine / pyrrolidine derivatives for inhibiting the activity of SHP2 and compositions thereof |
| JO3517B1 (en) | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| WO2016196591A1 (en) | 2015-06-01 | 2016-12-08 | Indiana University Research & Technology Corporation | Protein tyrosine phosphatases or shp2 inhibitors and uses thereof |
| CN112625028A (en) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | Compounds and compositions for inhibiting SHP2 activity |
| JP6878316B2 (en) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Compounds and compositions for inhibiting the activity of SHP2 |
| US10256121B2 (en) | 2015-07-06 | 2019-04-09 | Tokyo Electron Limited | Heated stage with variable thermal emissivity method and apparatus |
| WO2017100279A1 (en) | 2015-12-09 | 2017-06-15 | West Virginia University | Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent |
| ES2863873T3 (en) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | KRAS G12C inhibitors |
| KR20220124275A (en) | 2016-06-07 | 2022-09-13 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
| US10689377B2 (en) | 2017-11-15 | 2020-06-23 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
-
2019
- 2019-12-05 EA EA202190630A patent/EA202190630A1/en unknown
- 2019-12-05 SG SG11202102357RA patent/SG11202102357RA/en unknown
- 2019-12-05 MX MX2021002804A patent/MX2021002804A/en unknown
- 2019-12-05 CA CA3112129A patent/CA3112129A1/en active Pending
- 2019-12-05 US US17/275,181 patent/US20220079947A1/en active Pending
- 2019-12-05 WO PCT/US2019/064707 patent/WO2020118066A1/en unknown
- 2019-12-05 CN CN201980077511.4A patent/CN113164418A/en active Pending
- 2019-12-05 AU AU2019392683A patent/AU2019392683A1/en active Pending
- 2019-12-05 EP EP19893444.0A patent/EP3890716A4/en active Pending
- 2019-12-05 KR KR1020217008639A patent/KR20210113587A/en unknown
- 2019-12-05 JP JP2021513314A patent/JP2022509724A/en active Pending
-
2021
- 2021-03-09 IL IL281348A patent/IL281348A/en unknown
- 2021-03-25 ZA ZA2021/02016A patent/ZA202102016B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112129A1 (en) | 2020-06-11 |
| AU2019392683A1 (en) | 2021-04-01 |
| US20220079947A1 (en) | 2022-03-17 |
| JP2022509724A (en) | 2022-01-24 |
| WO2020118066A1 (en) | 2020-06-11 |
| EP3890716A4 (en) | 2022-12-21 |
| CN113164418A (en) | 2021-07-23 |
| IL281348A (en) | 2021-04-29 |
| ZA202102016B (en) | 2022-06-29 |
| EP3890716A1 (en) | 2021-10-13 |
| MX2021002804A (en) | 2021-07-15 |
| EA202190630A1 (en) | 2021-10-11 |
| KR20210113587A (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102016B (en) | Combination therapies | |
| IL274407A (en) | Combination therapies | |
| IL263680A (en) | Combination therapies | |
| IL277336A (en) | Combination therapy | |
| IL291659A (en) | Combination therapies | |
| EP3849535A4 (en) | Combination therapies | |
| ZA202102015B (en) | Combination therapies | |
| GB201800761D0 (en) | Interaction between blockchains | |
| EP3860609A4 (en) | Combination therapies | |
| EP3849536A4 (en) | Combination therapies | |
| ZA202102727B (en) | Immunoablative therapies | |
| EP3849534A4 (en) | Combination therapies | |
| HK1243598A1 (en) | Combination therapies | |
| EP3849537A4 (en) | Combination therapies | |
| IL281526A (en) | Rail-switching unit | |
| IL280968A (en) | Combination therapy | |
| IL279908A (en) | Combination therapy | |
| IL276999A (en) | Breastshield unit | |
| EP3844177A4 (en) | Combination therapies | |
| GB201805799D0 (en) | b | |
| GB201916906D0 (en) | Combination therapies | |
| IL280729A (en) | Combination therapy | |
| GB201807046D0 (en) | Combination | |
| IL287667A (en) | Combination therapies | |
| GB201807887D0 (en) | Combination |